Altimmune, Inc. ALT posted a loss for the second quarter on Tuesday. The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's ...

UBS lowered the firm’s price target on Altimmune (ALT) to $24 from $26 and keeps a Buy rating on the shares. Despite the IMPACT Phase 2b trial setback, UBS still sees a sizeable opportunity for ...

Q2 2025 Earnings Call Transcript August 12, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.32. Operator: Good morning, ladies and gentlemen, and ...

NasdaqGM:ALT 1 Year Share Price vs Fair Value Explore Altimmune's Fair Values from the Community and select yours ...

Altimmune Inc (ALT) reports a robust cash reserve and significant progress in drug trials, despite ongoing financial losses ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...

Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors ...

National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise ...

Altimmune (NASDAQ:ALT) shares surge 8% post-promising Q2 results, driven by pemvidutide's success in metabolic and liver conditions. Read more here.

Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Benzinga APIs. For real-time access ...

Altimmune, Inc. ( NASDAQ: ALT) Q2 2025 Earnings Call August 12, 2025 8:30 AM ET Gregory L. Weaver - Chief Financial Officer Scott Harris - Corporate Participant Vipin K. Garg - President, CEO & ...

Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you suffered purchased or acquired securities in Altimmune between August 10, 2023 and ...